Accurate interpretation of genetic and biomarker testing results is essential to better inform and target therapy and is highlighted by rapid advances in multiple tumor types. In the community practice setting, understanding the impact of testing on treatment decisions reinforces shared decision-making practices. In particular, underserved patients and those with low socioeconomic and low health literacy status report poor familiarity with testing terminology and are not able to accurately explain the role of testing in treatment. Community oncologists are positioned to intervene and facilitate better patient outcomes through enhanced patient education.
In the third installment of this CME Outfitters Snack series, expert faculty will discuss the role of predictive biomarkers in guiding clinical decision-making, practical guidance for testing requirements and recommendations, and shared decision-making. Faculty will also present illustrative examples of utilizing testing to guide therapy.
Employ strategies to provide genetic counseling for patients with cancer.
Supported by an educational grant from Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co., Inc.
Physicians, physician associates (PAs), nurse practitioners (NPs), nurses and pharmacists specializing in pathology, oncology or surgical oncology caring for patients with cancer in community settings.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Arun reports the following financial relationships:
Grants: Department of Defense (DOD); Cancer Prevention & Research Institute of Texas (CPRIT); National Cancer Institute (NCI); and Susan G. Komen
Research Support: AstraZeneca (paid to the institution)
Dr. Coleman reports the following financial relationships:
Advisory Board: AbbVie Inc.; Agenus Inc.; Alkermes; AstraZeneca; Clovis Oncology; Deciphera Pharmaceuticals, Inc.; Genelux; Genelux Corporation; Genmab; GSK; ImmunoGen, Inc.; OncoQuest Inc.; OncXerna Therapeutics, Inc.; Regeneron Pharmaceuticals Inc.; Roche/Genentech, Inc.; Merck & Co., Inc.; and Novocure
Grants: AstraZeneca; Clovis Oncology; Genelux Corporation; Genmab; ImmunoGen, Inc.; Roche/Genentech, Inc.; and Roche/Genentech, Inc.
Other Financial or Material Support: DOD Academy; GOG Foundation Inc. (mentor grant); Internal Displacement Monitoring Centre (IDMC); and National Comprehensive Cancer Network (NCCN)
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).